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Summary
 
Chemokines regulate a number of biological processes, including trafficking of diverse leuko-
cytes and proliferation of myeloid progenitor cells. SHP-1 (Src homology 2 domain tyrosine
phosphatase 1), a phosphotyrosine phosphatase, is considered an important regulator of signal-
ing for a number of cytokine receptors. Since specific tyrosine phosphorylation of proteins is
important for biological activities induced by chemokines, we examined the role of SHP-1 in
functions of chemokines using viable motheaten (me
 
v
 
/me
 
v
 
) mice that were deficient in SHP-1.
Chemotactic responses to stromal call–derived factor 1 (SDF-1), a CXC chemokine, were en-
hanced with bone marrow myeloid progenitor cells as well as macrophages, T cells, and B cells
from me
 
v
 
/me
 
v
 
 versus wild-type (
 
1
 
/
 
1
 
) mice. SDF-1–dependent actin polymerization and ac-
tivation of mitogen-activated protein kinases were also greater in me
 
v
 
/me
 
v
 
 versus 
 
1
 
/
 
1
 
 cells.
In contrast, immature subsets of me
 
v
 
/me
 
v
 
 bone marrow myeloid progenitors were resistant to
effects of a number of chemokines that suppressed proliferation of 
 
1
 
/
 
1
 
 progenitors. These al-
tered chemokine responses did not appear to be due to enhanced expression of CXCR4 or
lack of chemokine receptor expression. However, expression of some chemokine receptors
(CCR1, CCR2, CCR3, and CXCR2) was significantly enhanced in me
 
v
 
/me
 
v
 
 T cells. Our re-
sults implicate SHP-1 involvement in a number of different chemokine-induced biological ac-
tivities.
Key words: chemokine • Src homology 2 domain tyrosine phosphatase 1 • viable motheaten 
mice • chemotaxis • myelosuppression • stromal cell–derived factor 1
 
T
 
he control of cell migration and proliferation involves
a dynamic equilibrium between positive and negative
signals that sets a threshold of responsiveness to extracellular
stimuli. Migration and proliferation of hematopoietic cells
is controlled by a number of cytokines and chemokines.
Chemokines are small (
 
,
 
10 kD) chemotactic cytokines
that have a number of additional biological functions (1–5).
In addition to guiding leukocyte trafficking, chemokines
regulate proliferation of hematopoietic progenitor cells,
suppress or enhance angiogenesis, activate and differentiate
lymphocytes, and inhibit HIV infection. The role of
chemokines in hematopoiesis and trafficking of hematopoi-
etic progenitor cells (HPCs)
 
1
 
 has been emphasized by the
severely abnormal phenotype of mice deficient in a CXC
chemokine, stromal cell–derived factor 1 (SDF-1), or its
receptor, CXCR4 (6–8). These mutant mice were not via-
ble, had low numbers of B cell progenitors in fetal liver and
bone marrow, and had low numbers of myeloid progeni-
 
1
 
Abbreviations used in this paper:
 
 CFU-GM, colony forming unit-granulo-
cyte and macrophage; HPC, hematopoietic progenitor cell; JAK, Janus
kinase; MAPK, mitogen-activated protein kinase; me, motheaten; me
 
v
 
,
viable motheaten; SDF-1, stromal cell–derived factor 1; SHP-1, Src ho-
mology 2 domain tyrosine phosphatase 1. 
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tors in the bone marrow but normal numbers in the fetal
liver, implying the involvement of SDF-1 in trafficking and
differentiation of HPCs. SDF-1 induces chemotaxis of ma-
ture leukocytes such as lymphocytes and monocytes (9) and
their immature progenitor cells (10–12), but not of granu-
locytes (9). Although information on chemokine-induced
signaling pathways has been accumulating, it is still in its in-
fancy, and biological effects for many of these intracellular
molecules in these pathways have not been evaluated. It has
been reported that SDF-1 and other chemokines induce
signaling processes involving receptor-associated heterotri-
meric GTPases, phospholipase C, calcium mobilization,
phosphatidylinositol-3 kinase (PI-3K), small GTPases, and
diverse protein tyrosine kinases (13–16).
Motheaten (me) and viable motheaten (me
 
v
 
) mice are
defective in expression and activity of the Src homology 2
domain tyrosine phosphatase 1 (SHP-1) due to mutations
in the SHP-1 gene (17–19). SHP-1
 
 
 
is a
 
 
 
cytoplasmic phos-
phatase that is involved in the regulation of cellular activa-
tion, proliferation, and survival (20–22). Expression of
SHP-1 is largely restricted to hematopoietic cells. SHP-1 is
a negative regulator of signaling through diverse receptors,
including c-fms; the receptor for CSF 1; c-Kit, the receptor
for steel factor; the killer cell inhibitory receptor; the eryth-
ropoietin receptor; CD22; and the B cell and T cell antigen
receptors (for review see references 20–22). SHP-1 mutant
mice are defective in hematopoiesis and suffer from severe
combined immunodeficiency and systemic autoimmunity
due to aberrant regulation of hematopoiesis and activation
of leukocytes, exhibiting various defects. These include
characteristic skin and foot lesions, patchy loss of hair, slow
growth, short life span, splenomegaly, lymphadenopathy,
progressive thymic involusion, neutrophilia, lymphopenia,
pneumonitis, elevated serum immunoglobulins, absence
of terminal deoxynucleotidyl transferase-positive (TdT
 
1
 
)
cells, and immune complex deposition in the skin and kid-
neys (23).
Since tyrosine phosphorylation is important in chemo-
kine signaling processes, we investigated whether the phos-
photyrosine phosphatase SHP-1 played a role in regulating
chemokine responses using immature and mature hemato-
poietic cells from me
 
v
 
/me
 
v
 
 and wild-type (
 
1
 
/
 
1
 
) littermate
mice. We found that SHP-1–deficient hematopoietic pro-
genitor cells and mature leukocytes from the me
 
v
 
/me
 
v
 
 mice
demonstrated altered biological responses to chemokines.
This reveals a novel function of SHP-1 as an intermediary
factor for chemokine-induced signaling and biological ac-
tivities.
 
Materials and Methods
 
Mice.
 
Homozygous viable motheaten (me
 
v
 
) mice (C57BL/
6J-me
 
v
 
 strain) used in this study were from The Jackson Labora-
tory, propagated by heterozygote (
 
1
 
/me
 
v
 
) sibling matings. Wild-
type (
 
1
 
/
 
1
 
), 
 
1
 
/me
 
v
 
, and homozygous (me
 
v
 
/me
 
v
 
) mice were
genotyped by PCR. The me
 
v
 
 allele was detected (35 cycles; 1
min at 94
 
8
 
C, 1 min at 63
 
8
 
C, 1 min at 72
 
8
 
C) using two primers:
5
 
9
 
 GGT GGA GAA GAA AGG CCG GGA 3
 
9
 
 (me
 
v
 
–specific
forward primer) and 5
 
9
 
 TAT CAG GCT TGG CAG CAA AC
3
 
9
 
 (common reverse primer). The wild-type allele was detected
(35 cycles; 1 min at 94
 
8
 
C, 1 min at 64
 
8
 
C, 1 min at 72
 
8
 
C) using
primers 5
 
9
 
 GGT GGA GAA AGG CCG GGT 3
 
9
 
 (wild-type
SHP-1–specific forward primer) and 5
 
9
 
 TAT CAG GCT TGG
CAG CAA AC 3
 
9
 
 (common reverse primer). Sex- and age-
matched adult me
 
v
 
/me
 
v
 
 mice and 
 
1
 
/
 
1
 
 littermates (
 
z
 
4 wk old)
were used in this study.
 
Cell Isolation.
 
Total mouse bone marrow cells were aspirated
from two femurs of each mouse. Total bone marrow cells were
used for chemotaxis and suppression assays of HPCs. Total sple-
nocytes were prepared by crushing spleens through iron meshes.
Low density spleen mononuclear cells were recovered after den-
sity-cut on Lympholyte-M (Cedarlane Labs.). CD4
 
1
 
 T cells were
isolated from the low density splenocytes by staining with biotin-
labeled antibodies to CD4 (clone L3T4; PharMingen) followed
by positively selecting the stained CD4
 
1
 
 T cells using streptavidin
beads and magnets (Miltenyi Biotech). Isolated CD4
 
1
 
 T cells
were 
 
$
 
95% pure by CD4 expression.
 
Assays of HPC Proliferation and Cycling.
 
Total bone marrow
cells were plated at 5 
 
3
 
 10
 
4
 
, and total splenocytes were plated at
5 
 
3
 
 10
 
5
 
/ml in 1.0% methylcellulose culture medium containing
growth factors (30% vol/vol fetal bovine serum [Hyclone], 1 U/ml
recombinant human erythropoietin [Amgen Biologicals], 50 ng/ml
recombinant murine steel factor [Immunex Corp.], 5% vol/vol
pokeweed mitogen mouse spleen cell–conditioned medium [24],
and 0.1 mM hemin [Eastman-Kodak Co.]). Colonies derived
from granulocyte-macrophage (CFU-GM), erythroid (BFU-E),
and multipotential (CFU-GEMM) progenitor cells were scored
after 7 d of incubation in a humidified environment at 5% CO
 
2
 
and lowered (5%) O
 
2
 
 as previously described (24).
The percentage of progenitors in S-phase was estimated by the
high specific activity tritiated thymidine kill technique (24). Ab-
solute numbers of progenitors per organ were calculated based on
the number of viable, total nucleated cells per femur or spleen,
and on the number of colonies scored per number of cells plated.
For assessment of suppression of CFU-GM, total bone marrow
cells were plated in the presence of the 1.0% methylcellulose cul-
ture medium containing growth factors as noted above in the ab-
sence or presence of control medium, or purified recombinant
preparations of murine TNF-
 
a
 
 or IFN-
 
g
 
, each at 10 ng/ml, or
100 ng/ml of various human chemokines (MIP-1
 
a
 
, MCP-1, ex-
odus, SLC, TECK, MIP-4, CK
 
b
 
-11, IL-8, IP-10, MIG, ENA78,
GCP-2, lymphotactin, MCP-4 fractalkine, and MIP-1
 
b
 
). These
cytokine/chemokine concentrations have previously been shown
to be optimal for inhibition of colony formation by bone marrow
progenitor cells from mice of different strains. IFN-
 
g
 
, TNF-
 
a
 
,
and most chemokines were purchased from R&D Systems, ex-
cept for CK
 
b
 
-11, which was purified from Chinese hamster
ovary cells (25).
 
Quantitative Chemotaxis Assay of HPCs and Various Mature Leu-
kocytes.
 
Quantitative chemotaxis assays using transwells (6.5-
mm diameter, 5-
 
m
 
m pore size, polycarbonate membrane; Costar)
have been described previously (11, 12). For chemotaxis of
HPCs, 5 
 
3
 
 10
 
5
 
 total bone marrow cells were used for each
chemotaxis chamber. SDF-1 (obtained from Dr. Ian Clark-
Lewis, University of British Columbia, Vancouver, Canada) was
added to the lower chamber at various concentrations. Chemo-
taxis was allowed for 4 h. Input cells and cells migrating to the
lower chamber were collected, and assayed for colony forming
cells in methylcellulose culture containing the growth factors
noted above. Cells from two transwells were combined to obtain
enough numbers of HPCs for triplicated colony assays. Cells were 
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plated at 5 
 
3
 
 10
 
4
 
 per 1 ml methylcellulose culture medium. After 7 d,
colonies deriving from CFU-GM were differentially counted us-
ing standard techniques under an inverted microscope (24).
Chemotaxis of mouse leukocytes has been described previ-
ously (12). 5 
 
3
 
 10
 
5
 
 low density mononuclear cells were used for
input cells for chemotaxis of B and T lymphocytes and bone mar-
row macrophages. Chemotaxis was allowed for 3 h at 37
 
8
 
C. In-
put cells and cells migrating to the lower chambers were col-
lected. For collection of bone marrow macrophages, cells
attached to the bottom of culture plates were detached by incu-
bating in 5 mM EDTA/PBS (pH 7.4) for 20 min followed by ex-
tensive pipetting. Input cells and cells migrating to the lower
chamber were stained with antibodies (anti-CD11b/Mac-1–
TRIcolor and anti-F4/80–FITC for bone marrow macrophages;
anti-B220–PE or anti-IgM–PE, anti-CD4–Cychrome and anti-
CD8–FITC for splenic lymphocytes) and analyzed by FACscan
 
®
 
(Becton Dickinson) in a time-based manner for 20 s. Anti-CD4–
Cychrome (clone L3T4), anti-CD8a–FITC (clone Ly-2), anti-
B220 (clone RA3-6B2), and IgM-PE (clone Igh-6b) were pur-
chased from PharMingen. Anti-F4/80–FITC was purchased
from Serotec. Anti-Mac-1–TRIcolor was purchased from Caltag
Labs. Migration of each subset was normalized for numbers of
each subset of input cells.
 
Assay of Chemokine-induced Actin Polymerization.
 
Actin poly-
merization assays were performed as previously described by oth-
ers (26) with some modification. Cells were resuspended in
RPMI 1640 medium supplemented with 0.1% BSA at 10
 
6
 
 cells/ml.
SDF-1 was added at various concentrations (2, 20, 200, and
2,000 ng/ml) to the cell solution, and at a peak time point (25 s
after treatment with SDF-1), 0.1 ml of FITC-labeled phalloidin
solution (4 
 
3
 
 10
 
2
 
7
 
 M FITC-labeled phalloidin, 0.5 mg/ml 1-
 
a-lyso-
phosphatidylcholine, and 18% formaldehyde in PBS, all from
Sigma Chemical Co.) was added to 0.4 ml of cell solution to stain
and fix cells. Cells were incubated for 10 min at 378C, pelleted,
and resuspended in 0.5 ml of 2% paraformaldehyde solution.
Mean fluorescence was measured by FACscan®.
Mitogen-activated Protein Kinase and SHP-1 Phosphorylation As-
says. Spleen CD41 T lymphocytes from wild-type and mev/
mev mice were suspended in RPMI 1640 medium with 10% FCS
and preincubated at 378C for 10 min. The kinase assay was car-
ried out as previously reported (27). In brief, 5 3 106 cells were
stimulated with SDF-1 at 2 mg/ml for 60 s and lysed in RIPA
buffer. 250 mg of cell lysate was immunoprecipitated with anti–
Erk 1 polyclonal antibody and protein A–Sepharose 4B beads.
The immunocomplex was then washed twice with HNTG (20 mM
Hepes, pH 7.5, 150 mM NaCl, 0.1% Triton X-100, 10% glyc-
erol, and 1 mM Na3VO4) and once with kinase buffer (20 mM
Hepes, pH 7.5, 10 mM MgCl2, 2 mM 2-ME, and 1 mM
Na3VO4). The reaction was carried out in a mixture containing
20 ml of kinase buffer, 1 mg/ml myelin basic protein, 80 mM
ATP, and 0.075 mCi/ml [g-32P]ATP at 308C for 10 min. The
beads were spun down, and 18 ml of supernatant was spotted
onto P81 Whatman paper. The papers were then washed five
times with 180 mM phosphoric acid and once with ethanol, then
air dried and counted on a Beckman scintillation counter. For
SHP-1 phosphorylation and association of SHP-1 with PI-3K,
anti–SHP-1 polyclonal antibody (Santa Cruz Biotechnology) was
used to immunoprecipitate SHP-1 from cell lysates of splenic
CD41 T cells or murine FDCP-1 cells activated as described
above. Immunoprecipitates were resolved in SDS-PAGE and
blotted with antiphosphotyrosine antibodies (Upstate Biotech-
nology, Inc.) and then with anti–SHP-1 antibody or anti–PI-3K
P85 (Upstate Biotechnology, Inc.) as previously described (27, 28).
RNase Protection Assays of Chemokine Receptor Expression. To-
tal RNA was isolated from various sources of cells, including
bone marrow (total bone marrow cells) and spleen (low density
mononuclear cells and isolated CD41 T cells) using Trizol solu-
tion (GIBCO BRL). Multiprobe RNase protection template sets
mCR5 (CCR1, CCR1b, CCR3, CCR4, CCR5, CCR2, L32,
and GAPDH) and mCR6 (CXCR2, CXCR4, CXCR5, L32,
and GAPDH) were purchased from PharMingen. High specific
activity RNA probes were in vitro transcribed in the presence of
[a-32P]UTP (3,000 Ci/mmol; 10 mCi/ml; Amersham Life Sci-
ence) using T7 RNA polymerase included in the in vitro tran-
scription kit (PharMingen) according to manufacturer’s instruc-
tions. Probes and total RNA were allowed to hybridize and
treated with RNAse A and T1, and followed by proteinase K
treatment using RPA kit (PharMingen). The protected RNAs
from the RNAse treatment were resolved on 8 M urea/5% acryl-
amide sequencing gels. Filters were dried, exposed on X-ray film
(X-OMAT; Eastman-Kodak Co.), and analyzed for band radio-
activity using a phospho-image analyzer (Molecular Image Ana-
lyzer; Bio-Rad). Each band’s radio intensity was normalized for
L32 internal control, and averaged expression levels from three to
four independent experiments were plotted in Fig. 5 C.
Statistical Analysis. Student’s t test was used to analyze data
for significance. P , 0.05 was considered significant.
Results
Enhanced Chemotaxis of mev/mev HPCs toward SDF-1.
SDF-1, expressed ubiquitously in many organs including
bone marrow and lymphoid tissues, induces chemotaxis of
HPCs. It has been suggested that SDF-1 is a chemoattrac-
tant that induces the homing and retaining of progenitor
cells in bone marrow (11, 29). Thus far, SDF-1 is the only
Figure 1. Enhanced chemotaxis of mev/mev myeloid progenitors to
SDF-1. Bone marrow myeloid progenitor cells (CFU-GM, progenitors
of granulocytes and macrophages) were examined for their ability to
transmigrate from the upper chamber towards SDF-1 at indicated con-
centrations in the lower chamber. After chemotaxis, myeloid progenitors
in input and progenitors migrating to the lower chamber were assayed by
methylcellulose colony assay. CFU-GM migration was normalized for the
number of input CFU-GM to obtain CFU-GM migration rate (% of in-
put 6 SD). *Significant differences were observed between 1/1 and
mev/mev cells (P , 0.05). Results are from one experiment representative
of five independent experiments.684 SHP-1 Regulates Chemokine Responses
chemokine shown to induce chemotaxis of early stage my-
eloid and lymphoid progenitors. We examined the chemo-
tactic responsiveness of CFU-GM (progenitor cells for
granulocytes and macrophages) in bone marrow of mev/mev
mice and 1/1 littermates. The background migration of
CFU-GM in 1/1 mice and mev/mev mice was very low
(Fig. 1). In response to SDF-1, a typical bell-shaped
chemotactic response was observed for 1/1 progenitors
(Fig. 1). Bone marrow CFU-GM from mev/mev mice
demonstrated a much higher chemotaxis rate (.50%) than
their 1/1 counterparts (slightly .10%). Also, mev/mev
progenitors began to migrate at lower concentrations of
SDF-1 than 1/1 progenitors, demonstrating an increased
sensitivity of mev/mev CFU-GM to the chemotactic effect
of SDF-1.
SHP-1 Deficiency Makes Myeloid Progenitor Cells Resistant
to Chemokines that Suppress Proliferation. The suppressive ac-
tivity of chemokines for proliferation of immature subsets
of HPCs is a distinct biological activity from their chemo-
tactic activity. Thus far, 21 chemokines that cross the CC,
CXC, and C subfamilies have demonstrated such suppres-
sive activity (30). Among these chemokines, we tested 14
myelosuppressive chemokines (MIP-1a, MCP-1, exodus,
SLC, TECK, MIP-4, CKb-11, IL-8, IP-10, MIG,
ENA78, GCP-2, lymphotactin, and MCP-4) for their ef-
fects on colony formation of bone marrow CFU-GM.
These chemokines cross the CC, CXC, and C families of
chemokines. As controls, we included two previously de-
termined nonsuppressive chemokines (fractalkine, a CX3C
member, and MIP-1b, a CC member). As shown in Fig. 2,
all 14 suppressive chemokines, but not the 2 nonsuppres-
sive chemokines at an optimal concentration (100 ng/ml),
significantly inhibited proliferation of 1/1 littermate con-
trol CFU-GM. In contrast, none of the tested chemokines
inhibited the proliferation of mev/mev myeloid progenitor
cells (Fig. 2). As additional controls for suppression, TNF-a
Figure 2. Resistance of mev/mev progenitor cells
to myelosuppressive chemokines. Bone marrow
cells from wild-type and mev mice were plated into
methylcellulose culture medium in the presence of
either PBS, 100 ng/ml chemokines, or 10 ng/ml
TNF-a or IFN-g. Colony formation of CFU-GM
was assessed after 7 d of incubation. Results shown
are the average (mean 6 SD) for four separate ex-
periments.
Table I. Cycling Status and Absolute Numbers of Myeloid Progenitor Cells in Marrow and Spleen of 1/1 and mev/mev Mice
Cycling rates of progenitors
(% in S phase) Absolute No. progenitors (3 1023)/organ
Nucleated
cellularity CFU-GM BFU-E CFU-GEMM CFU-GM BFU-E CFU-GEMM
Marrow 3 1026
1/1 27 6 4 39 6 3 38 6 2 23.2 6 2.6 2.8 6 0.2 1.7 6 0.2 22 6 1.3
mev/mev 54 6 3 53 6 6 59 6 6 24.6 6 2.2 2.4 6 0.5 1.5 6 0.2 14 6 0
P value ,0.001 ,0.04 ,0.004 NS (,0.03) NS (.0.05) NS (.0.05) ,0.001
Spleen
1/1 10 6 10 0 6 00  6 0 6.9 6 2.1 3.5 6 1.2 1.1 6 0.3 166 6 14
mev/mev 56 6 2 55 6 3 54 6 4 57.8 6 11.8 14.8 6 4.8 6.4 6 1.5 279 6 25
P value ,0.001 ,0.001 ,0.001 ,0.002 ,0.001 ,0.02 ,0.002
Results are given as mean 6 SEM for 10 1/1 and 10 mev/mev mice. Each mouse was assessed individually from a total of five separate experiments.685 Kim et al.
and IFN-g, previously shown to be suppressors of HPC
proliferation (31), were assessed. In contrast to the
chemokines, TNF-a and IFN-g demonstrated equally sig-
nificant suppressive activities for bone marrow CFU-GM
from both mev/mev and 1/1 mice.
The suppressive activities of chemokines are directly re-
lated to the percentage of HPCs in the S-phase of the cell
cycle. The higher the percentage of HPCs in S-phase, the
greater the inhibition by chemokines (2). Therefore, we
examined the cycling status (percentage in S-phase of the
cell cycle) of CFU-GM, BFU-E, and CFU-GEMM in the
bone marrow of mev/mev and 1/1 control mice as esti-
mated by high specific activity tritiated thymidine kill assay
(24). CFU-GM, BFU-E, and CFU-GEMM in the bone
marrows of mev/mev mice were more actively proliferating
(a greater percentage of HPCs in S-phase) than were these
cells in 1/1 mice (Table I). Thus, the inability of CFU-
GM, BFU-E, and CFU-GEMM in the marrow of mev/mev
mice to respond to inhibition by chemokines could not be
attributed to lack of cycling HPCs. The difference in cy-
cling of CFU-GM, BFU-E, and CFU-GEMM in mev/mev
and 1/1 spleens was far greater than that of bone marrow
progenitors demonstrating the especially enhanced prolifer-
ation states of mev/mev progenitors in spleen (Table I).
Since myeloid progenitor cells from mev/mev mice were
more active in chemotaxis to SDF-1, and were not inhib-
ited by a number of suppressive chemokines, it would be
expected that the spleen and bone marrow of these mice
would have more blood cells. In this regard, splenomegaly
and abnormal hematopoiesis (excessive erythropoiesis and
myelopoiesis) in the spleens of mev mice have been previ-
ously reported by others (32). Thus we also examined the
absolute numbers of myeloid progenitor cells in spleen and
bone marrow (Table I). Spleens from mev/mev mice had
far greater numbers of myeloid progenitors (8.4 times more
CFU-GM, 4.2 times more BFU-E, and 5.8 times more
CFU-GEMM per organ) than did those from 1/1 mice.
Although the absolute numbers of progenitors in the mar-
rows of mev/mev and 1/1 mice were similar, the fre-
quency of myeloid progenitors in marrow from mev/mev
mice was higher than in 1/1 mice, as the nucleated cellu-
larity of mev/mev mice was significantly decreased (perhaps
due to the smaller size of mev/mev mice).
Enhanced Motility and Chemotaxis of mev/mev T Cells, B
Cells, and Macrophages from Bone Marrow and Spleen to SDF-1.
To determine whether mature leukocyte populations have
any altered chemotactic responses, we tested leukocytes in
spleen and bone marrow from mev/mev and 1/1 mice.
Spleen lymphocytes, including CD41 T cells, CD81 T cells,
B2201 B cells, and bone marrow Mac-11F4/801 macro-
phages were tested for their chemotactic response to SDF-1.
We observed a twofold greater basal motility (an ability to
transmigrate through a porous membrane independently of
chemoattractants) in mev/mev CD41 T cells than in their
1/1 counterparts (Fig. 3, A and E). In response to SDF-1,
significantly more mev/mev CD41 spleen T cells migrated
than did 1/1 CD41 T cells. Splenic CD81 T cells from
mev/mev mice demonstrated a similar enhancement in
chemotaxis to SDF-1 at all concentrations tested (Fig. 3, B
and E). B2201 B cells in spleen (Fig. 3, C and E) and bone
marrow F4/801 macrophages (Fig. 3, D and E) from mev/
mev mice also showed significantly enhanced chemotaxis to
Figure 3. Enhanced chemo-
taxis of mev/mev T cells (spleen
CD41 T cells and CD81 T
cells), spleen B2201 B cells, and
bone marrow macrophages in
response to SDF-1. Numbers of
cells migrating to the lower
chamber containing SDF-1 at
the indicated concentrations
were expressed as a percentage of
input cells in the upper chamber
at the start time of chemotaxis.
Input cells and cells migrated to the lower chambers were quantitatively
phenotyped by staining with mAbs (see Materials and Methods) followed
by flow cytometric analysis. Data are expressed as the mean (6 differ-
ence) of percentage of cell migration obtained from duplicated points (A,
B, C, and D). *Significant differences were observed between the 1/1
and mev/mev cells (P , 0.05 for A, B, C, and D). Results are from one
representative experiment of four to seven similar experiments. In E,
basal migration to medium (med) and chemotaxis to SDF-1 at 200 ng/ml
of 1/1 (1) and mev/mev (2) cells from a number of experiments are
shown. The horizontal bars represent mean values. In F, another
chemokine, SLC, was used along with SDF-1 to examine chemotaxis of
spleen CD41 T cells from 1/1 and mev/mev mice to a different
chemokine. P values for differences in basal migration and chemotaxis
between 1/1 and mev/mev cells respectively are 0.003 and 0.0006 for
CD41 T cells (n 5 10), 0.00006 and 0.0032 for CD81 T cells (n 5 6),
0.01 and 0.015 for B cells (n 5 7), and 0.025 (chemotaxis) for macro-
phages (n 5 6).686 SHP-1 Regulates Chemokine Responses
SDF-1. However, in response to another chemokine, SLC,
that is a more efficacious chemoattractant than SDF-1 for
murine CD41 T cells (12), no enhancement of CD41 T
cell chemotaxis has been observed, demonstrating the dif-
ferential effect of SHP-1 on chemotaxis to chemokines
(Fig. 3 F).
SDF-1-induced Actin Polymerization and Mitogen-activated
Protein Kinase Activation in mev/mev Cells. Chemokines bind
and activate G protein–coupled receptors followed by acti-
vation of various signaling molecules, leading to reorgani-
zation of actin cytoskeletal structures. Chemokine-depen-
dent actin polymerization is an important event for cell
motility, cell polarization, and formation of membrane
structures such as uropods. The latter is implicated in adhe-
sion to other cells and extracellular matrix proteins. To
evaluate changes in intracellular events, we compared the
basal and chemokine-induced levels of polymerized actin
(F-actin) in cells from mev/mev and 1/1 mice. The basal
levels of F-actin in splenic lymphocytes (Fig. 4 A) and
more specifically in splenic CD41 T cells (Fig. 4 B) from
mev/mev mice were greatly increased when compared with
their 1/1 counterparts (Fig. 4, A and B). When treated
with SDF-1 at various concentrations, 1/1 splenic lym-
phocytes and CD41 T cells increased cellular F-actin in a
dose-dependent manner (Fig. 4). Splenocytes and CD41 T
cells from the mev/mev mice demonstrated a similar trend
of actin polymerization to 1/1 counterparts in response to
SDF-1. The overall F-actin content of mev/mev cells was
greater than that of 1/1 cells after activation with SDF-1,
demonstrating greater cellular activity of actin polymerization.
Mitogen-activated protein kinase (MAPK) is activated in
response to SDF-1 in a CXCR4-overexpressed cell line
(15). We examined whether this downstream pathway of
SDF-1 signaling was altered in mev/mev cells. MAPK ac-
tivity in wild-type spleen CD41 T cells was consistently in-
duced in response to SDF-1 to 1.5-fold of basal level (Fig.
4 C). In mev/mev CD41 T cells, MAPK activity was in-
duced to 2.5 fold of basal level, demonstrating an enhanced
activation of MAPK. SHP-1 was constitutively tyrosine-
phosphorylated at a low level, and did not get more phos-
phorylated in response to SDF-1 in splenic T cells or in a
growth factor–dependent mouse cell line, FDCP-1, which
underwent chemotaxis in response to SDF-1 (data not
shown). We also observed that there was no induced associa-
tion of SHP-1 with a known positive signaling factor, PI-3K,
in response to SDF-1 in FDCP-1 cells (data not shown).
Expression of Chemokine Receptors in mev/mev and 1/1
Mice. Expression of chemokine receptors is tightly regu-
lated depending on the types, and states of activation and
differentiation of cells. We examined the possibility that
the altered biological activities of chemokines might be at-
tributed to changes in receptor expression in mev/mev ver-
sus 1/1 cells. We performed RNase protection assays to
measure transcripts of various mouse chemokine receptors,
including the CXC chemokine receptors CXCR2,
CXCR4, and CXCR5, and the CC chemokine receptors
CCR1, CCR1b, CCR2, CCR3, CCR4 and CCR5 in
cells from bone marrow and spleen. Expression of
CXCR4, the receptor for SDF-1, did not change in mev/mev
versus 1/1 cells from bone marrow, spleen, and CD41 T
cells (Fig. 5, A and C). Expression of CXCR2, a receptor
for IL-8, GCP-2, GRO-a, -b, -g, ENA-78, and NAP-2,
was enhanced in leukocytes from bone marrow and spleen,
and in spleen CD41 T cells. The enhancement of expres-
sion of CXCR2 in mev/mev CD41 T cells and splenocytes
was especially notable (Fig. 5 A). Expression of CXCR5,
the receptor for BLC/BCA-1, was detected at high levels
in 1/1 splenocytes, and at low levels in mev/mev spleno-
cytes. B cells were the major expression source of CXCR5
Figure 4. Enhanced actin polymerization and MAPK activity of mev/
mev cells in response to SDF-1. Spleen lymphocytes (A) and spleen CD41
T cells (B, purity .95%) were untreated or activated with SDF-1 at the
indicated concentrations to induce actin polymerization. Peak levels of
F-actin at 25 s after activation were monitored by FACScan® after FITC-
phalloidin staining of polymerized actin. Results shown are representative
of three different experiments each. For C, isolated CD41 T cells (5 3
106) were treated with SDF-1 (2,000 ng/ml) or control buffer (C) for 60 s.
MAPKs were immunoprecipitated from 250 mg of cell lysates and kinase
activity was measured with myelin basic protein as a substrate. Results
from three independent experiments are averaged (6 SD) and shown in
cpm (left) and induction fold from the basal level of each group (right).
*Significant difference was observed between 1/1 and mev/mev cells (P ,
0.036).687 Kim et al.
in 1/1 splenocytes (data not shown), and the drastic de-
crease of CXCR5 expression appears to be due to defi-
ciency of B cells in mev/mev spleen. In this regard, num-
bers of B2201 or IgM1 B cells were heavily reduced in
mev/mev spleen. B cells made up 40–50% of 1/1 versus
,15% of mev/mev total splenocytes. Expression of CCR1,
a receptor for MIP-1a and RANTES, was greatly en-
hanced in mev/mev CD41 T cells and splenocytes versus
their 1/1 counterparts. Expression of CCR2 (a receptor
for MCP-1 to MCP-5) was enhanced in mev/mev CD41 T
cells versus 1/1 cells. Expression of CCR3 (a receptor for
eotaxin-1 and -2 and MCP-2 and -4), CCR4 (a receptor
for TARC and MDC), and CCR5 (a receptor for MIP-1a
and -1b and RANTES) was very low in 1/1 and mev/mev
CD41 T cells and total bone marrow cells.
Discussion
In this paper we present evidence that SHP-1 is a novel
regulator of chemokine-mediated biological effects. Two
major biological activities, chemotaxis and suppression of
proliferation, have been examined in this study. SHP-1–defi-
cient immature and mature hematopoietic cells manifest
enhanced chemotaxis to a CXC chemokine SDF-1. Actin
polymerization and MAPK activation in SHP-1–deficient
cells were also hyperresponsive to SDF-1. In contrast, the
deficiency of SHP-1 abolished the sensitivity of immature
progenitors to suppression by chemokines.
Cellular responses to chemokines are presumably regu-
lated by equilibrium of a number of positive and negative
signaling factors. It has been reported that chemokine-medi-
ated biological activities involve several positive factors in-
cluding PI-3K (15), mitogen-activated protein kinases (Erk
1 and Erk 2) (15, 33), adenylate cyclase (34), and Janus ki-
nase 2 (JAK2) (13). As a negative signaling factor, serine/
threonine kinases such as b-adrenergic receptor kinase 2
can act as a desensitization factor for chemokine receptor–
mediated signaling (35, 36). SHP-1 negatively regulates a
number of signaling pathways by dephosphorylating pro-
teins on specific tyrosine residues. So far, the putative sub-
strates for SHP-1 include receptors such as IL-3R (37), B
cell CD22 receptor (38), B cell receptor Ig-a subunit (39),
killer cell inhibitory receptor (40), platelet endothelial cell
adhesion molecule-1 (41), IL-2Rb (42), and CD72 (43), as
well as other intracellular proteins such as JAK1 and JAK3
(42), JAK2 (44), ZAP-70 (45), and p56lck (46). Chemo-
kine-induced biological activities can be inhibited by spe-
cific tyrosine kinase inhibitors such as genistein (a general
Figure 5. Expression of chemokine receptors in mev/mev mice compared with 1/1 mice. Freshly isolated bone marrow cells (BM), spleen mononu-
clear cells (Spleen), and CD41 T cells (purity .95%) from 1/1 and mev/mev mice were analyzed for expression of chemokine receptor mRNA by
RNase protection assay. L32 and GAPDH were included as internal controls to normalize expression of chemokine receptors in different mice and cell
types. Expression of CXC chemokine receptors is shown in A and that of CC chemokine receptors is shown in B. Each band’s radiointensity was mea-
sured by phosphor-image analyzer (Molecular Image Analyzer; Bio-Rad) to quantitate expression of chemokine receptors. Normalized expression levels
of chemokine receptors for L32 internal control (expression of chemokine receptor/expression of L32) from three independent experiments were aver-
aged, and are shown in C.688 SHP-1 Regulates Chemokine Responses
tyrosine kinase inhibitor) (14, 47), tyrphostin B42 (a spe-
cific JAK2 kinase inhibitor) (13), and PD98059 (an inhibi-
tor of the Erk pathways) (48), suggesting the importance of
tyrosine phosphorylation in chemokine-induced signaling.
The effectiveness of these inhibitors depends on cell types,
chemokines, and types of biological effects. For future
study, it will be important to identify the target protein(s)
of SHP-1 that can modify chemokine responses.
The observations of a dichotomy in response of mev/mev
cells to chemokines was of interest. Although mev/mev
cells are enhanced in chemotaxis (hyperresponse), they are
resistant to myelosuppressive chemokines in proliferation
(hyporesponse). Chemotactic activity and myelosuppressive
effect are very distinct biological activities in terms of ki-
netics, cell target specificity, and cellular signaling machin-
ery. Specifically, 21 chemokines out of 34 that had been
tested previously have myelosuppressive activity, inhibiting
the proliferation of immature subsets of bone marrow cells
that are responsive to stimulation by combinations of
growth factors (30). In contrast, only three chemokines,
SDF-1, SLC, and CKb-11, out of many that were ana-
lyzed, have been demonstrated to have chemotactic activi-
ties for human myeloid progenitors (10, 11, 49, 50). SDF-1
is a chemoattractant for CFU-GM, BFU-E, and CFU-
GEMM (10, 11), whereas SLC and CKb-11 are mainly
chemotactic for the macrophage progenitors (CFU-M), a
subset of CFU-GM (49, 50). Chemokine-induced chemo-
taxis occurs quickly and depends on chemokine gradients,
whereas inhibition of myeloid progenitor cells by chemo-
kines is dependent on concentrations rather than gradients
of chemokines. Chemotaxis involves cell motility and cy-
toskeletal machinery to migrate, including reorganization
of actin structures, adhesion to and detachment from sub-
stratum, and termination of movement by desensitization.
On the other hand, inhibition of myeloid cell proliferation
by chemokines presumably requires regulation of cell cycle
and mitogenic signaling machinery. Although further stud-
ies on the differential signaling for these two biological
processes are required, our results suggest that the mecha-
nism of SHP-1 in regulation of suppression is probably dif-
ferent from that of chemotaxis. It is possible that SHP-1
dephosphorylates different target signaling proteins that are
directly involved in or indirectly set optimal conditions for
signaling for chemotaxis and suppression. The inability of
mev/mev myeloid progenitor cells to respond to chemo-
kines is reminiscent of the insensitivity of malignant my-
eloid progenitor cells from some patients with leukemia to
suppression by chemokines (2, 51).
The activity of chemokines can be regulated in two ways
in the cells: modification of chemokine receptor expression
and/or signaling pathways. In this study, we examined
whether SHP-1 modulates chemokine receptor expression.
Expression of CXCR4, the receptor for SDF-1, did not
change in mev/mev versus 1/1 cells. Thus it does not ap-
pear that the enhanced chemotactic response to SDF-1 can
be attributed to enhanced CXCR4 expression. In bone
marrow cells from mev/mev mice, we observed similar or
slightly enhanced expression of many chemokine receptors,
including those that are shown to bind many of the myelo-
suppressive chemokines. Thus lack of suppression of mev/mev
progenitors in response to chemokines is probably not due
to loss of chemokine receptor expression. Leukocytes in
mev/mev mice show similar profiles of chemokine receptor
expression to that of activated cells. In mev/mev CD41 T
cells, expression of a number of chemokine receptors (es-
pecially CXCR2, CCR2, CCR1, CCR2, and CCR3) is
much higher than in the 1/1 counterparts. It is difficult,
at this time, to pinpoint the direct cause for the enhanced
expression of some chemokine receptors in mev/mev T
cells. However, there are several possibilities: (a) absence of
SHP-1 directly induces expression of these chemokine re-
ceptors; (b) absence of SHP-1 activates cells and activated
cells express more chemokine receptors; and/or (c) the
pathological environment in mev/mev (e.g., autoimmunity)
induces expression of cytokines that in turn drive the acti-
vation of T cells and induction of chemokine receptors.
Taken together, our results suggest that SHP-1 deficiency
in me mice alters myeloid progenitor and mature leukocyte
responses to chemokines.
This work was supported by U.S. Public Health Service grants RO1 DK53674, R01 HL56416, and R01
HL54037; by a project in P01 HL 53586 from the National Institutes of Health (NIH) to H.E. Broxmeyer; and
NIH RO1 CA78606, R29 GM53660, and American Cancer Society RPG-98-273-01-TBE grants to G.-S. Feng.
Address correspondence to Hal E. Broxmeyer, Department of Microbiology/Immunology and the Walther
Oncology Center, Indiana University School of Medicine, Bldg. R4, Rm. 302, 1044 West Walnut St., In-
dianapolis, IN 46202. Phone: 317-274-7510; Fax: 317-274-7592; E-mail: hbroxmey@iupui.edu
C.H. Kim’s present address is Dept. of Pathology, L235, Stanford University School of Medicine, Stanford,
CA 94304.
Submitted: 23 March 1999 Revised: 27 May 1999 Accepted: 1 July 1999
References
1. Baggiolini, M., B. Dewald, and B. Moser. 1997. Human
chemokines: an update. Annu. Rev. Immunol. 15:675–705.
2. Broxmeyer, H.E., S. Cooper, N. Hague, L. Benninger, A.
Sarris, K. Cornetta, S. Vadhan-Raj, P. Hendrie, and C. Man-
tel. 1995. Human chemokines: enhancement of specific ac-
tivity and effects in vitro on normal and leukemic progenitors689 Kim et al.
and a factor-dependent cell line and in vivo in mice. Ann.
Hematol. 71:235–246.
3. Kim, C.H., and H.E. Broxmeyer. 1999. Chemokines: signal
lamps for trafficking of T- and B-cells for development and
effector function. J. Leukocyte Biol. 65:6–15.
4. Luster, A.D. 1998. Chemokines—chemotactic cytokines that
mediate inflammation. N. Engl. J. Med. 12:436–445.
5. Rollins, B.J. 1997. Chemokines. Blood. 90:909–928.
6. Nagasawa, T., S. Hirota, K. Tachibana, N. Takakura, S.
Nishikawa, Y. Kitamura, N. Yoshida, H. Kikutani, and T.
Kishimoto. 1996. Defects of B-cell lymphopoiesis and bone-
marrow myelopoiesis in mice lacking the CXC chemokine
PBSF/SDF-1. Nature. 382:635–638.
7. Tachibana, K., S. Hirota, H. Iizasa, H. Yoshida, K. Kawa-
bata, Y. Kataoka, Y. Kitamura, K. Matsushima, N. Yoshida,
S.-i. Nishikawa, et al. 1998. The chemokine receptor
CXCR4 is essential for vascularization of the gastrointestinal
tract. Nature. 393:591–594.
8. Zou, Y.-R., A.H. Kottmann, M. Kuroda, I. Taniuchi, and
D.R. Littman. 1998. Function of the chemokine receptor
CXCR4 in haematopoiesis and in cerebellar development.
Nature. 393:595–599.
9. Bleul, C.C., R.C. Fuhlbrigge, J.M. Casasnovas, A. Aiuti, and
T.A. Springer. 1996. A highly efficacious lymphocyte
chemoattractant, stromal cell-derived factor 1 (SDF-1). J.
Exp. Med. 184:1101–1109.
10. Aiuti, A., I.J. Webb, C. Bleul, T. Springer, and J.C. Gutier-
rez Ramos. 1997. The chemokine SDF-1 is a chemoattrac-
tant for human CD341 hematopoietic progenitor cells and
provides a new mechanism to explain the mobilization of
CD341 progenitors to peripheral blood. J. Exp. Med. 185:
111–120.
11. Kim, C.H., and H.E. Broxmeyer. 1998. In vitro behavior of
hematopoietic progenitor cells under the influence of
chemoattractants: SDF-1, steel factor and the bone marrow
environment. Blood. 91:100–110.
12. Kim, C.H., L.M. Pelus, J.R. White, and H.E. Broxmeyer.
1998. Differential chemotactic behavior of developing T cells
in response to thymic chemokines. Blood. 91:4434–4443.
13. Mellado, M., J.M. Rodriguez-Frade, A. Aragay, G. del Real,
A.M. Martin, A.J. Vila-Coro, A. Serrano, F. Mayor, Jr., and
A.C. Martinez. 1998. The chemokine monocyte chemotac-
tic protein 1 triggers Janus kinase 2 activation and tyrosine
phosphorylation of the CCR2B receptor. J. Immunol. 161:
805–813.
14. Suzuki, M., K. Hirai, S. Kitani, T. Takaishi, H. Kihara, T.
Kasahara, K. Ito, and Y. Morita. 1996. Pharmacologic study
of basophil histamine release induced by monocyte chemo-
tactic protein-1 with kinase inhibitors. Int. Arch. Allergy Im-
munol. 111:18–22.
15. Ganju, R.K., S.A. Brubaker, J. Meyer, P. Dutt, Y. Yang, S.
Qin, W. Newman, and J.E. Groopman. 1998. The alpha-
chemokine, stromal cell-derived factor-1alpha, binds to the
transmembrane G-protein-coupled CXCR-4 receptor and
activates multiple signal transduction pathways. J. Biol. Chem.
273:23169–23175.
16. Laudanna, C., J.J. Campbell, and E.C. Butcher. 1996. Role
of Rho in chemoattractant-activated leukocyte adhesion
through integrins. Science. 271:981–983.
17. Shultz, L.D., P.A. Schweitzer, T.V. Rajan, T. Yi, J.N. Ihle,
R.J. Matthews, M.L. Thomas, and D.R. Beier. 1993. Muta-
tions at the murine motheaten locus are within the hemato-
poietic cell protein-tyrosine phosphatase (Hcph) gene. Cell.
73:1445–1454.
18. Kozlowski, M., I. Mlinaric-Rascan, G.S. Feng, R. Shen, T.
Pawson, and K.A. Siminovitch. 1993. Expression and cata-
lytic activity of the tyrosine phosphatase PTP1C is severely
impaired in motheaten and viable motheaten mice. J. Exp.
Med. 178:2157–2163.
19. Tsui, H.W., K.A. Siminovitch, L. de Souza, and F.W. Tsui.
1993. Motheaten and viable motheaten mice have mutations
in the haematopoietic cell phosphatase gene. Nat. Genet. 4:124–
129.
20. Plas, D.R., and M.L. Thomas. 1998. Negative regulation of
antigen receptor signaling in lymphocytes. J. Mol. Med. 76:
589–595.
21. Siminovitch, K.A., and B.G. Neel. 1998. Regulation of B
cell signal transduction by SH2-containing protein-tyrosine
phosphatases. Semin. Immunol. 10:329–347.
22. Healy, J.I., and C.C. Goodnow. 1998. Positive versus nega-
tive signaling by lymphocyte antigen receptors. Annu. Rev.
Immunol. 16:645–670.
23. Shultz, L.D., T.V. Rajan, and D.L. Greiner. 1997. Severe
defects in immunity and hematopoiesis caused by SHP-1
protein-tyrosine-phosphatase deficiency. Trends Biotechnol.
15:302–307.
24. Cooper, S., and H.E. Broxmeyer. 1996. Measurement of in-
terleukin-3 and other hematopoietic growth factors, such as
GM-CSF, G-CSF, M-CSF, and erythropoietin and the po-
tent co-stimulating cytokines steel factor and Flt3 ligand.
Curr. Prot. Immunol. 18(Suppl.):6.4.1–6.4.12.
25. Kim, C.H., L.M. Pelus, J.R. White, E. Applebaum, K. Jo-
hanson, and H.E. Broxmeyer. 1998. CK beta-11/macrophage
inflammatory protein-3 beta/EBI1-ligand chemokine is an
efficacious chemoattractant for T and B cells. J. Immunol.
160:2418–2424.
26. Howard, T.H., and W.H. Meyer. 1984. Chemotactic pep-
tide modulation of actin assembly and locomotion. J. Cell
Biol. 98:1265–1271.
27. Qu, C.-K., Z.-Q. Shi, R. Shen, F.-Y. Tsai, S.H. Orkin, and
G.-S. Feng. 1999. A deletion mutation in the SH2-N do-
main of Shp-2 severely suppresses hematopoietic cell devel-
opment. Mol. Cell. Biol. 17:5499–5507.
28. Anzai, N., A. Gotoh, H. Shibayama, and H.E. Broxmeyer.
1999. Modulation of integrin function in hematopoietic pro-
genitor cells by CD43 engagement: possible involvement of
protein tyrosine kinase and phospholipase C-gamma. Blood.
93:3317–3326.
29. Peled, A., I. Petit, O. Kollet, M. Magid, T. Ponomaryov, T.
Byk, A. Nagler, H. Ben-Hur, A. Many, L. Shultz, et al.
1999. Dependence of human stem cell engraftment and re-
population of NOD/SCID mice on CXCR4. Science. 283:
845–848.
30. Broxmeyer, H.E., and C.H. Kim. 1999. Regulation of he-
matopoiesis in a sea of chemokine family members with a
plethora of redundant activities. Exp. Hematol. 27:1113–1123.
31. Broxmeyer, H.E. 1996. Myelosuppressive cytokines and pep-
tides.  In Blood Cell Biochemistry, Vol 7: Hematopoietic
Growth Factors. T. Whetton and T. Gordon, editors. Ple-
nem, London, UK. 121–150.
32. Shultz, L.D., D.R. Coman, C.L. Bailey, W.G. Beamer, and
C.L. Sidman. 1984. “Viable motheaten,” a new allele at the
motheaten locus. I. Pathology. Am. J. Pathol. 116:179–192.
33. Shyamala, V., and H. Khoja. 1998. Interleukin-8 receptors
R1 and R2 activate mitogen-activated protein kinases and
induce c-fos, independent of Ras and Raf-1 in Chinese ham-690 SHP-1 Regulates Chemokine Responses
ster ovary cells. Biochemistry. 37:15918–15924.
34. del Pozo, M.A., P. Sanchez-Mateos, M. Nieto, and F.
Sanchez-Madrid. 1995. Chemokines regulate cellular polar-
ization and adhesion receptor redistribution during lympho-
cyte interaction with endothelium and extracellular matrix.
Involvement of cAMP signaling pathway. J. Cell Biol. 131:
495–508.
35. Franci, C., J. Gosling, C.L. Tsou, S.R. Coughlin, and I.F.
Charo. 1996. Phosphorylation by a G protein-coupled kinase
inhibits signaling and promotes internalization of the mono-
cyte chemoattractant protein-1 receptor. Critical role of car-
boxyl-tail serines/threonines in receptor function. J. Immu-
nol. 157:5606–5612.
36. Aramori, I., S.S. Ferguson, P.D. Bieniasz, J. Zhang, B.
Cullen, and M.G. Cullen. 1997. Molecular mechanism of
desensitization of the chemokine receptor CCR-5: receptor
signaling and internalization are dissociable from its role as an
HIV-1 co-receptor. EMBO (Eur. Mol. Biol. Org.) J. 16:
4606–4616.
37. Yi, T., A.L. Mui, G. Krystal, and J.N. Ihle. 1993. Hemato-
poietic cell phosphatase associates with the interleukin-3 (IL-
3) receptor beta chain and down-regulates IL-3-induced ty-
rosine phosphorylation and mitogenesis. Mol. Cell. Biol. 13:
7577–7586.
38. Law, C.L., S.P. Sidorenko, K.A. Chandran, Z. Zhao, S.H.
Shen, E.H. Fischer, and E.A. Clark. 1996. CD22 associates
with protein tyrosine phosphatase 1C, Syk, and phospholi-
pase C-gamma(1) upon B cell activation. J. Exp. Med. 183:
547–560.
39. Pani, G., M. Kozlowski, J.C. Cambier, G.B. Mills, and K.A.
Siminovitch. 1995. Identification of the tyrosine phosphatase
PTP1C as a B cell antigen receptor-associated protein in-
volved in the regulation of B cell signaling. J. Exp. Med. 181:
2077–2084.
40. Berg, K.L., K. Carlberg, L.R. Rohrschneider, K.A. Simino-
vitch, and E.R. Stanley. 1998. The major SHP-1-binding,
tyrosine-phosphorylated protein in macrophages is a member
of the KIR/LIR family and an SHP-1 substrate. Oncogene.
17:2535–2541.
41. Hua, C.T., J.R. Gamble, M.A. Vadas, and D.E. Jackson.
1998. Recruitment and activation of SHP-1 protein-tyrosine
phosphatase by human platelet endothelial cell adhesion mol-
ecule-1 (PECAM-1). Identification of immunoreceptor ty-
rosine-based inhibitory motif-like binding motifs and sub-
strates. J. Biol. Chem. 273:28332–28340.
42. Migone, T.S., N.A. Cacalano, N. Taylor, T. Yi, T.A. Wald-
mann, and J.A. Johnston. 1998. Recruitment of SH2-con-
taining protein tyrosine phosphatase SHP-1 to the interleukin
2 receptor; loss of SHP-1 expression in human T-lym-
photropic virus type I-transformed T cells. Proc. Natl. Acad.
Sci. USA. 95:3845–3850.
43. Wu, Y., M.J. Nadler, L.A. Brennan, G.D. Gish, J.F. Timms,
N. Fusaki, J. Jongstra-Bilen, N. Tada, T. Pawson, J. Wither,
et al. 1998. The B-cell transmembrane protein CD72 binds
to and is an in vivo substrate of the protein tyrosine phos-
phatase SHP-1. Curr. Biol. 8:1009–1017.
44. Klingmuller, U., U. Lorenz, L.C. Cantley, B.G. Neel, and
H.F. Lodish. 1995. Specific recruitment of SH-PTP1 to the
erythropoietin receptor causes inactivation of JAK2 and ter-
mination of proliferative signals. Cell. 80:729–738.
45. Plas, D.R., R. Johnson, J.T. Pingel, R.J. Matthews, M. Dal-
ton, G. Roy, A.C. Chan, and M.L. Thomas. 1996. Direct
regulation of ZAP-70 by SHP-1 in T cell antigen receptor
signaling. Science. 272:1173–1176.
46. Lorenz, U., K.S. Ravichandran, S.J. Burakoff, and B.G.
Neel. 1996. Lack of SHPTP1 results in src-family kinase hy-
peractivation and thymocyte hyperresponsiveness. Proc. Natl.
Acad. Sci. USA. 93:9624–9629.
47. Sozzani, S., D. Zhou, M. Locati, M. Rieppi, P. Proost, M.
Magazin, N. Vita, J. van Damme, and A. Mantovani. 1994.
Receptors and transduction pathways for monocyte chemo-
tactic protein-2 and monocyte chemotactic protein-3. Simi-
larities and differences with MCP-1. J. Immunol. 152:3615–
3622.
48. Ragozzino, D., A. Giovannelli, A.M. Mileo, C. Limatola, A.
Santoni, and F. Eusebi. 1998. Modulation of the neurotrans-
mitter release in rat cerebellar neurons by GRO beta. Neu-
roreport. 9:3601–3606.
49. Kim, C.H., L.M. Pelus, J.R. White, and H.E. Broxmeyer.
1998. MIP-3 beta/ELC/CKb-11 is a chemoattractant with a
specificity for macrophage progenitors among myeloid pro-
genitor cells. J. Immunol. 161:2580–2585.
50. Kim, C.H., and H.E. Broxmeyer. 1999. SLC/Exodus2/
6Ckine induces chemotaxis of hematopoietic progenitor
cells: Differential activity of ligands of CCR7, CXCR3, or
CXCR4 in chemotaxis vs. suppression of progenitor prolif-
eration. J. Leukocyte Biol. In press.
51. Eaves, C.J., J.D. Cashman, S.D. Wolpe, and A.C. Eaves.
1993. Unresponsiveness of primitive chronic myeloid leuke-
mia cells to macrophage inflammatory protein 1 alpha, an in-
hibitor of primitive normal hematopoietic cells. Proc. Natl.
Acad. Sci. USA. 90:12015–12019.